BackCSPC Pharmaceutical Group Limited. Overview

CSPC Pharmaceutical Group Limited. Net Tangible Assets

CSPC Pharmaceutical Group Limited.'s net tangible assets is $38B.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$38.48B
13.62% YoYΔ $4.61B vs prior year quarter

Peer trimmed avg / median

Loading

CSPC Pharmaceutical Group Limited. Net Tangible Assets History

Loading

CSPC Pharmaceutical Group Limited. vs. peers: Net Tangible Assets Comparison

Loading

CSPC Pharmaceutical Group Limited. Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

CSPC Pharmaceutical Group Limited. (CSPCY) FAQ

As of the most recent data (December 2025), CSPCY shows a net tangible assets of $38B. That compares with $34B in the prior-year period — up 13.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CSPCY's net tangible assets is now $38B (was $34B) — a 13.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether CSPC Pharmaceutical Group Limited. is outperforming or lagging.

Tracking CSPCY's net tangible assets over time shows whether CSPC Pharmaceutical Group Limited. is scaling, shrinking, or reshaping that part of the business. The current reading is $38B That compares with $34B in the prior-year period — up 13.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net tangible assets page, Stockcircle has CSPC Pharmaceutical Group Limited.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $38B) with ownership activity and broader fundamentals.

CSPC Pharmaceutical Group Limited.'s net tangible assets is $38B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.